As part of our virtual 'Partners & Platforms Seminars' series, the UK DRI is delighted to welcome Prof Chas Bountra.
'How can the Structural Genomics Consortium/Centre for Medicine Discovery partner with UK DRI to accelerate new biology and therapeutic discovery'
An introduction on the Structural Genomics Consortium – a not-for-profit public-private partnership developing accessible tools (including structural/chemical biology, antibodies, target enabling packages) to advance scientific knowledge and drug discovery.
Prof Chas Bountra
Professor of Translational Medicine; Chief Scientist Structural Genomics Consortium Oxford University
Tuesday 21 April, 11:30 - 12:30 BST
This event is open to UK DRI researchers and support staff only. Registration and associated Zoom links will be distributed via Centre Manager emails nearer the time of the event.
The Structural Genomics Consortium (SGC) is a not-for-profit, public-private partnership with the directive to carry out basic science of relevance to drug discovery. The core mandate of the SGC is to determine 3D structures on a large scale and cost-effectively - targeting human proteins of biomedical importance and proteins from human parasites that represent potential drug targets. In these two areas respectively, the SGC is now responsible for >25% and >50% of all structures deposited into the Protein Data Bank each year; to date (Sep.2011) the SGC has released the structures of over 1200 proteins with implications to the development of new therapies for cancer, diabetes, obesity, and psychiatric disorders.
The SGC is headed by Aled Edwards. Operations at each site are managed by a Chief Scientist - Cheryl Arrowsmith in Toronto, Canada and Chas Bountra in Oxford, UK.